<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364321</url>
  </required_header>
  <id_info>
    <org_study_id>QSNICH63-017</org_study_id>
    <nct_id>NCT04364321</nct_id>
  </id_info>
  <brief_title>Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention</brief_title>
  <official_title>The Efficacy of A Single Dose Clonazepam Compared With the Intermittent Diazepam to Prevent Recurrent Febrile Seizures in Queen Sirikit National Institute of Child Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Sirikit National Institute of Child Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Sirikit National Institute of Child Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the efficacy and safety of single dose clonazepam compared with intermittent oral
      diazepam for prevention of recurrent febrile seizures in children who had three or more
      febrile seizures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Febrile seizures are the most common type of seizures disorder of young children. The risk of
      recurrences are 33 percent overall, half of them had at least one recurrent seizure (the 3rd
      febrile seizures). After that the recurrent rate is 50-100 percent depend on their risk
      factors. A few studies found that multiple recurrent febrile seizures might associated with
      language developmental delayed, poor speed performance quotient, Attention deficit
      hyperactivity disorders. Moreover, seizures are upsetting both parents and children. During
      the febrile illness, the intermittent diazepam, continuous phenobarbital and valproate are
      effective for prevention of the recurrences. Because of the benign nature of a simple febrile
      seizures, the risks of side effects generally outweigh the benefits. However, there is no
      clinical guidelines for prevention of recurrent febrile seizures in the children who
      experienced multiple occurrences. The better prophylactic drug; safe, effective and easy to
      use, for prevention of recurrent febrile seizures in children with multiple recurrences might
      be needed. Clonazepam, the long half-life benzodiazepine, is commonly used for treatment of
      epilepsy may be effective in preventing recurrent febrile seizures. This study, a
      single-blind, randomized clinical trial, single dose clonazepam at the time of fever present
      compared with oral diazepam during the fever to prevent the recurrent febrile seizures.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A pragmatic parallel group randomized trial comparing single dose clonazepam with intermittent oral diazepam for prevention recurrent febrile seizures</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent rate of febrile seizures</measure>
    <time_frame>the assessment will be done at 12 months after enrollment</time_frame>
    <description>Rate of seizure occurs when the children have febrile illnesses (at the onset of fever until fever gone). The seizures will be reported by their parents/caregivers. (via the seizure record form and the interview.) Statistic analysis: Cumulative incidence (person-year). percent. Comparison between the two group by unpaired t test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse reaction of medications</measure>
    <time_frame>7 days</time_frame>
    <description>The adverse reactions will be recorded by their caregivers in the record form for 7 days since patients taking the medication (clonapam or diazepam).
The adverse reactions are drowsiness, ataxia, irritability, drooling, insomnia and rashes.
Statistic analysis: cumulative incidence (person-year), Comparison between the two group by unpaired t test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated factors: Sex</measure>
    <time_frame>at the enrollment.</time_frame>
    <description>To evaluate the associated factors of multiple recurrent febrile seizures.
The data will be collected in the record form by the primary investigator at the enrollment.
Statistic analysis: comparison between group by chi square</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated factors: age at first febrile seizure</measure>
    <time_frame>at the enrollment</time_frame>
    <description>To evaluate the associated factors of multiple recurrent febrile seizures.
The data will be collected in the record form by interviewing the caregivers to recall the information.
Statistic analysis: comparison between group by unpaired t test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated factors: the lowest temperature that cause seizure</measure>
    <time_frame>at the enrollment.</time_frame>
    <description>To evaluate the associated factors of multiple recurrent febrile seizures.
The data will be collected in the record form by interviewing the caregivers to recall the information.
Statistic analysis: comparison between group by unpaired t test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with febrile convulsions in parents or siblings</measure>
    <time_frame>at the enrollment.</time_frame>
    <description>To evaluate the associated factors of multiple recurrent febrile seizures.
The data will be collected in the record form by interviewing the caregivers.
Statistic analysis: comparison between group by chi square</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with epilepsy in parents or siblings</measure>
    <time_frame>at the enrollment.</time_frame>
    <description>To evaluate the associated factors of multiple recurrent febrile seizures.
The data will be collected in the record form by interviewing the caregivers.
Statistic analysis: comparison between group by chi square</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with type of febrile seizures (simple or complex)</measure>
    <time_frame>at the enrollment.</time_frame>
    <description>To evaluate the associated factors of multiple recurrent febrile seizures.
Type of febrile seizure
simple: seizure duration less than 15 min, generalized seizures, one seizure in 24 hours
complex:15 minutes or more and/or focal seizures and/or 2 or more seizures in 24 hours
The data will be collected in the record form by interviewing the caregivers.
Statistic analysis: comparison between group by chi square</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with delayed developmental milestones</measure>
    <time_frame>at the enrollment.</time_frame>
    <description>The data will be collected by the developmental screening tools; Age and Stages Questionaires, third edition reported by the caregivers. Scoring will be done by neurology pediatrician at the enrollment.
Age and Stages Questionaires(third editon) are divided in 5 areas; communication, gross motor, fine motor, problem solving, personal-social, each area has 6 questions. Scores for each area are between 0 to 60. The Cutoff points are different in each area. If the score is above the cutoff, the children development appears normal for age.
(The cutoff for communication is 29.65, Gross motor is 22.25, fine motor is 25.14, problem solving is 27.72 and personal-social is 25.34)
Statistic analysis: comparison between group by unpaired t test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Recurrent Febrile Convulsion</condition>
  <arm_group>
    <arm_group_label>Single dose Clonazepam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent oral diazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonazepam 0.5 MG</intervention_name>
    <description>Clonazepam 0.02 mg/kg only one dose</description>
    <arm_group_label>Single dose Clonazepam</arm_group_label>
    <other_name>Rivotril</other_name>
    <other_name>Povanil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam Tablets</intervention_name>
    <description>Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)</description>
    <arm_group_label>Intermittent oral diazepam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 6-60 months at date of enrollment

          -  3 or more episodes of clinically diagnosed febrile seizures

        Exclusion Criteria:

          -  history of afebrile seizures or any history suggested the epilepsy

          -  history of previous brain insults; CNS infection, birth trauma, traumatic brain
             injury.

          -  delayed developmental milestones

          -  abnormal neurological examinations

          -  currently treatment by continous antiepileptic drug(s)

          -  A contraindication to Clonazepam, Diazepam such as drug hypersensitivity, liver
             disease.

          -  Predictable lack of available of follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>60 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinjutha Nithiuthai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Sirikit National Institute of Child Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinjutha Nithiuthai, MD</last_name>
    <phone>+66806218033</phone>
    <email>jinjutha.nt@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sirorat Suwannachote, MD</last_name>
    <phone>662-354-8333</phone>
    <email>sirorat.s@rsu.ac.th</email>
  </overall_contact_backup>
  <link>
    <url>http://journals.sbmu.ac.ir/ijcn/article/view/1868</url>
    <description>Intermittent Clonazepam in the prevention of recurrent febrile seiziures</description>
  </link>
  <reference>
    <citation>Berg AT, Shinnar S, Darefsky AS, Holford TR, Shapiro ED, Salomon ME, Crain EF, Hauser AW. Predictors of recurrent febrile seizures. A prospective cohort study. Arch Pediatr Adolesc Med. 1997 Apr;151(4):371-8.</citation>
    <PMID>9111436</PMID>
  </reference>
  <reference>
    <citation>Berg AT, Shinnar S, Hauser WA, Leventhal JM. Predictors of recurrent febrile seizures: a metaanalytic review. J Pediatr. 1990 Mar;116(3):329-37.</citation>
    <PMID>2137875</PMID>
  </reference>
  <reference>
    <citation>Kölfen W, Pehle K, König S. Is the long-term outcome of children following febrile convulsions favorable? Dev Med Child Neurol. 1998 Oct;40(10):667-71.</citation>
    <PMID>9851235</PMID>
  </reference>
  <reference>
    <citation>Visser AM, Jaddoe VW, Ghassabian A, Schenk JJ, Verhulst FC, Hofman A, Tiemeier H, Moll HA, Arts WF. Febrile seizures and behavioural and cognitive outcomes in preschool children: the Generation R study. Dev Med Child Neurol. 2012 Nov;54(11):1006-11. doi: 10.1111/j.1469-8749.2012.04405.x. Epub 2012 Sep 3.</citation>
    <PMID>22937894</PMID>
  </reference>
  <reference>
    <citation>Bertelsen EN, Larsen JT, Petersen L, Christensen J, Dalsgaard S. Childhood Epilepsy, Febrile Seizures, and Subsequent Risk of ADHD. Pediatrics. 2016 Aug;138(2). pii: e20154654. doi: 10.1542/peds.2015-4654. Epub 2016 Jul 13.</citation>
    <PMID>27412639</PMID>
  </reference>
  <reference>
    <citation>Billstedt E, Nilsson G, Leffler L, Carlsson L, Olsson I, Fernell E, Gillberg C. Cognitive functioning in a representative cohort of preschool children with febrile seizures. Acta Paediatr. 2020 May;109(5):989-994. doi: 10.1111/apa.15059. Epub 2019 Nov 10.</citation>
    <PMID>31618476</PMID>
  </reference>
  <results_reference>
    <citation>Rosman NP, Colton T, Labazzo J, Gilbert PL, Gardella NB, Kaye EM, Van Bennekom C, Winter MR. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures. N Engl J Med. 1993 Jul 8;329(2):79-84.</citation>
    <PMID>8510706</PMID>
  </results_reference>
  <results_reference>
    <citation>Knudsen FU. Recurrence risk after first febrile seizure and effect of short term diazepam prophylaxis. Arch Dis Child. 1985 Nov;60(11):1045-9.</citation>
    <PMID>3907504</PMID>
  </results_reference>
  <results_reference>
    <citation>Capovilla G, Mastrangelo M, Romeo A, Vigevano F. Recommendations for the management of &quot;febrile seizures&quot;: Ad Hoc Task Force of LICE Guidelines Commission. Epilepsia. 2009 Jan;50 Suppl 1:2-6. doi: 10.1111/j.1528-1167.2008.01963.x. Review.</citation>
    <PMID>19125841</PMID>
  </results_reference>
  <results_reference>
    <citation>Offringa M, Newton R, Cozijnsen MA, Nevitt SJ. Prophylactic drug management for febrile seizures in children. Cochrane Database Syst Rev. 2017 Feb 22;2:CD003031. doi: 10.1002/14651858.CD003031.pub3. Review.</citation>
    <PMID>28225210</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Sirikit National Institute of Child Health</investigator_affiliation>
    <investigator_full_name>Kullasate Sakpichaisakul</investigator_full_name>
    <investigator_title>Director of Pediatric Neurology</investigator_title>
  </responsible_party>
  <keyword>recurrent febrile convulsions</keyword>
  <keyword>Clonazepam</keyword>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Seizures, Febrile</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazepam</mesh_term>
    <mesh_term>Clonazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make IPD available due to the confidentiality.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

